229 related articles for article (PubMed ID: 28869453)
1. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
[TBL] [Abstract][Full Text] [Related]
2. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
3. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
[TBL] [Abstract][Full Text] [Related]
4. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
5. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Zhang L; Ma YP; Jia G
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
[TBL] [Abstract][Full Text] [Related]
6. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
7. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
8. [Study of the effects
Tian Y; Li LH; Yang GZ; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):976-981. PubMed ID: 27995884
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
Kacı FN; Kiraz Y; Çekdemir D; Baran Y
Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
11. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
12. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
13. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
14. [Effects of cinobufagin on apoptosis in U-2OS osteosarcomas cells].
Cao F; Kang X; Wang L
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Mar; 28(3):349-53. PubMed ID: 24844018
[TBL] [Abstract][Full Text] [Related]
15. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway.
Wang Y; Zhang XL; Sun CM
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
18. [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
Deng Y; Tao SD; Zhang X; He ZM; Chen Y; Deng ZK; Li YY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1178-82. PubMed ID: 24156429
[TBL] [Abstract][Full Text] [Related]
19. [Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
Zhou NC; Liu BL; Qi MY; Xu B; Liu X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1331-5. PubMed ID: 25338583
[TBL] [Abstract][Full Text] [Related]
20. Changes in protein profiles of multiple myeloma cells in response to bortezomib.
Turan T; Sanlı-Mohamed G; Baran Y
Leuk Lymphoma; 2013 May; 54(5):1061-8. PubMed ID: 23025401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
